Skip to content
Screener

Capricor Therapeutics CAPR Total Liabilities & Equity

Total Liabilities & Equity at other companies

Pfizer logo
PfizerPFE
$207.62B-0.2%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$3.19B-13.4%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$2.87B+8.0%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$782.35M+13.0%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$1.08B+49.8%
Cytokinetics logo
CytokineticsCYTK
$1.92B+57.0%

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$236.86M-42.9%
Enterprise value$146.22M-62.7%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 5:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-060382
Line itemMarch 31, 2026 / (unaudited)December 31, 2025December 31, 2025
STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 57,664,673 and 57,370,909 shares issued and outstanding, respectively57,66557,371
Additional paid-in capital617,718,525610,330,105
Accumulated other comprehensive income(253,727)283,154
Accumulated deficit(338,819,830)(304,878,485)
TOTAL STOCKHOLDERS’ EQUITY278,702,633305,792,145
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$326,283,517$$355,949,294

Item 1. Financial Statements.

FAQ

What is Capricor Therapeutics's total liabilities & equity?
Capricor Therapeutics (CAPR) reported total liabilities & equity of $326.28M in Q1 2026.
How has Capricor Therapeutics's total liabilities & equity changed year-over-year?
Capricor Therapeutics's total liabilities & equity increased by 112.2% year-over-year, from $153.77M to $326.28M.
What is the long-term trend for Capricor Therapeutics's total liabilities & equity?
Over 5 years (2020 to 2025), Capricor Therapeutics's total liabilities & equity has grown at a 59.4% compound annual growth rate (CAGR), from $34.62M to $355.95M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Capricor Therapeutics's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude